Diabetes Medications - Metformin, SGLT2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas
Diabetes mellitus affects approximately 537 million adults worldwide according to the International Diabetes Federation, with prevalence projected to reach 783 million by 2045. It is one of the leading causes of blindness, kidney failure, heart attacks, stroke, and lower-limb amputation globally. The disease falls into two main types: type 1 diabetes (autoimmune destruction of insulin-producing pancreatic beta cells, typically diagnosed in childhood or young adulthood, requiring lifelong insulin) and type 2 diabetes (progressive insulin resistance with relative insulin deficiency, accounting for over 90% of all diabetes cases worldwide).
This catalogue focuses on oral and non-insulin injectable medications for type 2 diabetes management. Insulin (used in all type 1 and many type 2 patients) is typically supplied through specialised channels because of cold-chain requirements. Modern type 2 diabetes pharmacotherapy has expanded dramatically over the past two decades — from a handful of agents (metformin, sulfonylureas) to multiple classes targeting different aspects of glucose homeostasis: liver gluconeogenesis, insulin sensitivity, incretin signalling, kidney glucose reabsorption, and pancreatic insulin secretion.
Choosing the right agent depends on HbA1c target, weight goals, cardiovascular and kidney disease status, hypoglycaemia risk, and cost. Modern guidelines (ADA, EASD) now recommend SGLT2 inhibitors or GLP-1 agonists (when affordable) for patients with established cardiovascular disease, heart failure, or chronic kidney disease — even ahead of HbA1c targets — because of strong cardiovascular and renal benefits independent of glucose lowering.
🪨 Conditions This Category Treats
Type 2 diabetes mellitus is the dominant indication. It typically develops after age 40 in patients with risk factors including obesity, sedentary lifestyle, family history, gestational diabetes history, ethnicity (higher prevalence in South Asian, African, Caribbean, Hispanic populations), and metabolic syndrome (central obesity, hypertension, dyslipidaemia). Symptoms include polyuria, polydipsia, fatigue, blurred vision, and slow-healing wounds — though many type 2 diabetics are asymptomatic for years and diagnosed only on routine blood testing.
Prediabetes (HbA1c 5.7-6.4% or fasting glucose 5.6-6.9 mmol/L) affects an estimated 850 million people globally. Lifestyle intervention reduces progression to type 2 diabetes by 58% in landmark trials (DPP, Finnish DPS). Metformin in younger high-risk prediabetics reduces progression by approximately 31% and is supported by ADA guidelines as an option for selected patients.
Beyond glucose control, this category increasingly addresses cardiovascular and renal protection. SGLT2 inhibitors reduce heart failure hospitalisation by ~30% and progression of chronic kidney disease by similar magnitudes — benefits seen in diabetic AND non-diabetic patients. GLP-1 agonists reduce major adverse cardiovascular events. These pleiotropic benefits have transformed diabetes drug selection from pure glucose lowering to comprehensive cardio-renal protection.
💊 How Modern Diabetes Treatment Works
Metformin (Glucophage / Glycomet / Cytaroph / Janumet) primarily reduces hepatic gluconeogenesis through AMP-kinase activation, also modestly improves peripheral insulin sensitivity. The result is reduced fasting glucose and improved overall glycaemic control without hypoglycaemia or weight gain. The most common side effects are GI — diarrhea, nausea, abdominal discomfort — reduced by extended-release formulations or taking with meals. Lactic acidosis is extremely rare with appropriate dose adjustment in kidney impairment.
Sulfonylureas (glimepiride / Amaryl, glibenclamide, gliclazide / Diamicron, repaglinide / Prandin) stimulate insulin release from pancreatic beta cells. They are effective and inexpensive but cause hypoglycaemia and modest weight gain. They are no longer first-line because of these side effects but remain widely used worldwide because of low cost. Thiazolidinediones (pioglitazone / Actos) improve peripheral insulin sensitivity through PPAR-gamma activation. They have specific niche uses (some evidence for cardiovascular benefit in established CVD) but cause weight gain, fluid retention, and modest fracture risk.
DPP-4 inhibitors (sitagliptin in Janumet) and the broader class of incretin-based therapy enhance insulin release in response to meals and reduce glucagon — weight-neutral, low hypoglycaemia risk, modest HbA1c reduction. Alpha-glucosidase inhibitors (acarbose / Precose / Glucobay) slow carbohydrate absorption from the gut, reducing post-meal glucose spikes. Glycogen phosphorylase inhibitors and emerging agents (Cycloset / bromocriptine for circadian dopamine modulation in diabetes) round out the category. Each agent has distinct strengths and roles in combination regimens.
💊 Drug Classes in This Category
| Class | Best For | Examples |
|---|---|---|
| Biguanides | First-line for type 2 DM; PCOS-related insulin resistance; prediabetes | Glucophage, Glycomet, Cytaroph (metformin) |
| Sulfonylureas / meglitinides | Add-on when metformin insufficient; cost-sensitive settings | Amaryl (glimepiride), Diamicron (gliclazide), Prandin (repaglinide) |
| Thiazolidinediones | Insulin resistance; NASH; selected CVD risk reduction | Actos (pioglitazone) |
| DPP-4 inhibitor + biguanide combo | Type 2 DM needing both incretin and metformin effect; once-daily simplicity | Janumet (sitagliptin + metformin) |
| Alpha-glucosidase inhibitors | Post-prandial hyperglycaemia; carbohydrate-heavy meals | Glucobay, Precose (acarbose) |
| Dopamine agonists | Type 2 DM with circadian dysregulation; adjunctive use | Cycloset (bromocriptine) |
✅ How to Choose
- 🪨 Newly diagnosed type 2 diabetes → Glucophage / Glycomet (metformin) 500 mg twice daily with meals, titrated to 2000 mg daily over 4 weeks. Combine with lifestyle change.
- 🫀 Type 2 DM with established CVD or heart failure → add SGLT2 inhibitor (where available) or GLP-1 agonist alongside metformin. ADA/EASD recommend regardless of HbA1c.
- 💉 Metformin alone insufficient (HbA1c above target after 3 months) → add second agent. Janumet (DPP-4 + metformin combo) for once-daily simplicity, Amaryl / Diamicron for cost-sensitive cases.
- 🍲 Significant post-meal glucose spikes → add Glucobay (acarbose) — effective for high-carbohydrate diets, no hypoglycaemia risk, GI tolerance can be a limitation.
- 🍲 Lean type 2 DM with predominant insulin secretion deficit → consider Amaryl or Prandin (sulfonylurea / meglitinide) earlier in the algorithm.
- 🤱 Severe insulin resistance with metabolic syndrome / fatty liver → Actos (pioglitazone) 15-30 mg daily — weight gain and fluid retention are concerns.
- 🤰 Gestational diabetes or pregnancy planning → metformin is acceptable in pregnancy; insulin is the gold standard. Other oral agents typically discontinued.
❓ Frequently Asked Questions about Diabetes Medications
Why is metformin so widely prescribed?
Metformin has the best evidence base in all of diabetes care: lowers HbA1c 1-2%, weight-neutral, no hypoglycaemia, possible cardiovascular and longevity benefits, decades of safety data, low cost. The side effects (GI upset in 20-30% of users initially) usually settle within 2-3 weeks. Extended-release formulations and taking with meals minimise GI symptoms.
Do diabetes medications cause weight gain?
Depends on the class. Weight-neutral or weight-reducing: metformin, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 agonists, acarbose. Cause weight gain: sulfonylureas (1-3 kg), thiazolidinediones (2-5 kg), insulin (2-6 kg). For patients with obesity, modern guidelines favour weight-neutral or weight-loss-promoting options after metformin.
When is insulin needed for type 2 diabetes?
Insulin is added when oral and injectable non-insulin agents are insufficient to reach HbA1c targets, when there is significant glycaemic decompensation (HbA1c above 10% at diagnosis with symptoms), in pregnancy when oral agents are inadequate, during acute hospital illness, and in advanced kidney disease where many oral agents are contraindicated. Many type 2 diabetics eventually require insulin as beta-cell function declines over 10-20 years of disease.
Can lifestyle changes reverse type 2 diabetes?
For some patients, particularly those with short duration disease and significant weight loss, type 2 diabetes can enter remission — defined as HbA1c below 6.5% off all diabetes medications for at least 3 months. The DiRECT trial showed roughly 46% remission rate with intensive weight loss (15+ kg) in primary care. Bariatric surgery achieves remission in 60-80% of obese patients. Once diabetes is well-established (longer than 5-10 years), remission is less likely.
What is a good HbA1c target?
Targets are individualised: under 7% for most adults; under 6.5% for younger patients with shorter disease duration and no significant comorbidity; under 8% for older patients with significant comorbidities or limited life expectancy where strict control increases hypoglycaemia risk without proportionate benefit. Always consider hypoglycaemia risk alongside the HbA1c number.
How often should I check my blood sugar at home?
Depends on therapy. Insulin users: at least 4 times daily, often more. Sulfonylurea users: 1-2 times daily initially, less often once stable. Metformin or other non-hypoglycaemic agents alone: HbA1c every 3-6 months may suffice without daily checks. Continuous glucose monitoring (CGM) is increasingly accessible and useful for fine-tuning therapy and identifying overnight or post-meal patterns.
🩺 When to See a Healthcare Provider
Annual diabetes review includes HbA1c, kidney function (eGFR, urine albumin), foot examination, eye screening (annual retinopathy screen), lipid panel, blood pressure, weight, and assessment of cardiovascular risk. Seek prompt care for sudden severe symptoms: severe hyperglycaemia (glucose above 16 mmol/L / 300 mg/dL with vomiting, abdominal pain, deep rapid breathing — possible diabetic ketoacidosis), severe hypoglycaemia (confusion, loss of consciousness), or new foot ulcer or infection (high amputation risk if untreated).
Inform all healthcare providers about your full diabetes regimen including any over-the-counter or herbal products. Many medications interact with diabetes drugs: corticosteroids raise glucose; certain antibiotics affect sulfonylurea levels; ACE inhibitors potentiate hypoglycaemia. Plan ahead for travel, illness, and surgery — diabetes management changes during all three. Discuss vaccination status (annual flu, pneumococcal, COVID-19) at routine reviews because diabetic patients have higher infection risk.